William Blair & Company’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

William Blair & Company’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.17K	Buy	+28	New	+$1.15K	﹤0.01%	1905

Other funds holding BBC

KCP

Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $454M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

APW

Aurora Private Wealth Rockaway, New Jersey $140M AUM

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

William Blair & Company's BBC Position: Q1 2026 in Review

William Blair & Company opened a new position in Virtus Biotech Clinical Trials ETF (BBC) in Q1 2026: 28 shares worth $1.17K. The stake represents ﹤0.01% of the portfolio and ranks #1905 among its holdings.

20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.

William Blair & Company held 28 shares of Virtus Biotech Clinical Trials ETF worth $1.17K as of Q1 2026.
Virtus Biotech Clinical Trials ETF was a new William Blair & Company position in Q1 2026.
Virtus Biotech Clinical Trials ETF made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1905 holding.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.